

# James L Januzzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6385441/publications.pdf>

Version: 2024-02-01

566  
papers

65,916  
citations

2322

98  
h-index

911

241  
g-index

576  
all docs

576  
docs citations

576  
times ranked

45577  
citing authors

#	ARTICLE	IF	CITATIONS
1	First Trimester Cardiac Biomarkers among Women with Peripartum Cardiomyopathy: Are There Early Clues to This Late-Pregnancy Phenomenon?. <i>American Journal of Perinatology</i> , 2023, 40, 137-140.	1.4	2
2	Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 226-233.	1.7	4
3	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. <i>JACC: Heart Failure</i> , 2022, 10, 1-11.	4.1	11
4	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	11.4	29
5	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
6	Sex Differences in Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 477-498.	1.7	62
7	Cardiovascular benefit of SGLT2 inhibitors. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 142-155.	6.1	6
8	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1.	17.0	33
9	Multiple biomarkers for rapid rule-out of myocardial infarction: worth the added stress?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	1.0	0
10	Risk Prediction Scores in Cardiovascular Disease: Useful Tool or "Model of the Week". <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	1
11	21st Century CE. <i>Journal of the American College of Cardiology</i> , 2022, 79, 352-354.	2.8	0
12	Early B-Type Natriuretic Peptide Change in HFREF Patients Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2022, 10, 119-128.	4.1	15
13	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. <i>Journal of the American College of Cardiology</i> , 2022, 79, 432-444.	2.8	21
14	Periprocedural MI as an Endpoint in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 527-529.	2.8	3
15	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. <i>Nature Medicine</i> , 2022, 28, 809-813.	30.7	107
16	Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2022, 79, 617-628.	2.8	35
17	Cardiac remodelling "Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	7.1	29
18	Relation of High-Sensitivity Cardiac Troponin I and Obstructive Coronary Artery Disease in Patients Without Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2022, 173, 16-24.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Underdiagnosis of Ischemic Heart Disease in New-Onset Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 861-863.	2.8	1
20	Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. <i>European Journal of Heart Failure</i> , 2022, 24, 678-680.	7.1	1
21	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	2.8	36
22	Performance of a protein biomarker panel for prediction of cardiovascular events in patients with diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e270-e271.	1.8	1
23	Using Artificial Intelligence to Better Predict and Develop Biomarkers. <i>Heart Failure Clinics</i> , 2022, 18, 275-285.	2.1	5
24	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 266-275.	4.1	20
25	N-terminal pro-B-type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 87-99.	3.1	3
26	Practical outpatient management of worsening chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 750-761.	7.1	27
27	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	7.1	22
28	Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1427-1438.	5.3	14
29	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	3.1	15
30	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	3.1	1
31	A Biomarker-Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e025729.	3.7	4
32	Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. <i>JACC: Heart Failure</i> , 2022, 10, 512-524.	4.1	20
33	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 1670-1690.	8.6	109
34	Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography. <i>American Heart Journal</i> , 2022, 252, 51-59.	2.7	6
35	Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1869-1878.	7.1	21
36	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.	2.2	39

#	ARTICLE	IF	CITATIONS
37	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007440.	2.2	16
38	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136.	4.1	47
39	Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. <i>Diabetes Care</i> , 2021, 44, 210-216.	8.6	14
40	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 42-51.	4.1	20
41	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
42	Recurrent versus new-onset depressive symptoms: Relationships with biomarkers of cardiovascular health following acute coronary syndrome. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110291.	2.6	5
43	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 137-145.	4.1	27
44	Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients. <i>Clinical Chemistry</i> , 2021, 67, 79-86.	3.2	3
45	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , 2021, 26, 11-21.	3.9	1
46	Reverse Cardiac Remodeling and ARNI Therapy. <i>Current Heart Failure Reports</i> , 2021, 18, 71-83.	3.3	19
47	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
48	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 848-857.	2.8	50
49	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 772-810.	2.8	612
50	Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , 2021, 14, e007767.	3.9	23
51	Cardiovascular Risk Factors Are Associated With Future Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 48-58.	4.0	83
52	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	3.3	20
53	Incidence, Predictors, and Outcomes of Thrombotic Events in Hospitalized Patients With Viral Pneumonia. <i>American Journal of Cardiology</i> , 2021, 143, 164-165.	1.6	6
54	A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1357-1367.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630
56	Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1487-1499.	2.8	18
57	National and Local Politics of the Heart. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1744-1746.	2.8	0
58	Proteomics as a Path to More Refined Heart Failure Therapeutics. <i>JACC: Heart Failure</i> , 2021, 9, 278-280.	4.1	0
59	Can biomarkers help find the "sweet spot" for treating patients with diabetes?. <i>European Journal of Heart Failure</i> , 2021, 23, 1037-1039.	7.1	0
60	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021, 42, 1464-1475.	2.2	29
61	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 447-455.	2.4	7
62	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
63	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2021, 7, e06.	3.0	1
64	Gaining Efficiency in Clinical Trials With Cardiac Biomarkers. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1922-1933.	2.8	7
65	Downstream Cascades of Care Following High-Sensitivity Troponin Test Implementation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3171-3179.	2.8	15
66	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	3.7	6
67	Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. <i>American Journal of Cardiology</i> , 2021, 147, 61-69.	1.6	6
68	Obesity-Mediated Disruption of Natriuretic Peptide "Blood Pressure" Rhythms. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2304-2306.	2.8	2
69	Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1257-1265.	5.6	8
70	Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. <i>ESC Heart Failure</i> , 2021, 8, 2741-2754.	3.1	32
71	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). <i>American Journal of Cardiology</i> , 2021, 148, 146-150.	1.6	15
72	Association Between Angiotensin Receptor "Nephrilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	3.9	27

#	ARTICLE	IF	CITATIONS
73	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <sc>EMPEROR</sc>-Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30
74	Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. Circulation, 2021, 143, 2316-2318.	1.6	14
75	Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure. , 2021, 3, e0480.		5
76	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	1.7	2
77	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC: Heart Failure, 2021, 9, 497-505.	4.1	5
78	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
79	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1747-1760.	2.3	10
80	Lipoprotein(a) and Cardiovascular Diseases. JAMA - Journal of the American Medical Association, 2021, 326, 352.	7.4	30
81	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
82	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <sc>Europe</sc>. European Journal of Heart Failure, 2021, 23, 1432-1436.	7.1	10
83	Utility of High-Sensitivity Troponin Among Stable Patients With Chest Pain Undergoing Stress Imaging (from PROMISE). American Journal of Cardiology, 2021, 158, 148-149.	1.6	1
84	Untangling Myocardial Injury. Journal of the American College of Cardiology, 2021, 78, 791-793.	2.8	2
85	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
86	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	2.2	33
87	The Intersection of Type 2 Myocardial Infarction and Heart Failure. Journal of the American Heart Association, 2021, 10, e020849.	3.7	2
88	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<sc>HFA</sc>), European Society of Cardiology (<sc>ESC</sc>). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
89	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55
90	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	7.1	23

#	ARTICLE	IF	CITATIONS
91	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	4.2	15
92	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	4.1	20
93	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1242-1253.	2.8	7
94	Biomarkers and Imaging in Chest Pain. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1418-1420.	2.8	0
95	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. <i>Open Heart</i> , 2021, 8, e001704.	2.3	3
96	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. <i>PLoS ONE</i> , 2021, 16, e0258622.	2.5	6
97	Rebranding Natriuretic Peptides. <i>Clinical Chemistry</i> , 2021, 67, 4-5.	3.2	1
98	The Role of Lipoprotein(a) in Cardiovascular Diseases Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2078.	7.4	0
99	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE trial. <i>ESC Heart Failure</i> , 2021, , .	3.1	3
100	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 28-36.	1.5	1
101	Passivating High-Risk Plaques. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1561-1563.	5.3	0
102	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0
103	Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial Infarction: The Partners YOUNG-MI Registry. <i>American Journal of Medicine</i> , 2020, 133, 605-612.e1.	1.5	73
104	Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 185-187.	4.1	1
105	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	7.1	26
106	Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. <i>Clinical Infectious Diseases</i> , 2020, 71, 1306-1315.	5.8	2
107	It is time for consistency in the use of biomarkers in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 90-91.	7.1	2
108	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	3.9	18

#	ARTICLE	IF	CITATIONS
109	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	7.1	23
110	Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1345-1357.	2.8	47
111	Understanding the Mechanistic Benefit of Heart Failure Drugs Matters. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2752-2754.	2.8	7
112	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	4.1	12
113	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
114	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020, 8, 961-972.	4.1	15
115	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.1	93
116	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1117-1145.	2.8	276
117	Derivation and External Validation of a High-Sensitivity Cardiac Troponin-Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e017221.	3.7	12
118	Proteomic Signatures During Treatment in Different Stages of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006794.	3.9	10
119	Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 488.	7.4	391
120	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection?. <i>Clinical Chemistry</i> , 2020, 66, 1146-1149.	3.2	7
121	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2076-2085.	2.8	50
122	Feasibility and preliminary efficacy of a positive psychology-based intervention to promote health behaviors in heart failure: The REACH for Health study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110285.	2.6	16
123	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1455-1465.	2.8	54
124	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	7.1	21
125	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	27.0	2,821
126	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. <i>Clinical Cardiology</i> , 2020, 43, 1209-1215.	1.8	7



#	ARTICLE	IF	CITATIONS
127	Racial Differences in Serial NT-proBNP Levels in Heart Failure Management. <i>Circulation</i> , 2020, 142, 1018-1020.	1.6	14
128	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. <i>EClinicalMedicine</i> , 2020, 26, 100504.	7.1	44
129	Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018686.	3.7	46
130	Finding a Needle in a Haystack. <i>JACC Basic To Translational Science</i> , 2020, 5, 1043-1053.	4.1	15
131	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. <i>Diabetes Care</i> , 2020, 43, 1843-1850.	8.6	27
132	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e006946.	3.9	28
133	Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1664-1675.	3.1	19
134	Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. <i>Biomarkers in Medicine</i> , 2020, 14, 775-784.	1.4	5
135	Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. <i>Journal of the American College of Cardiology</i> , 2020, 76, 533-546.	2.8	592
136	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	4.1	53
137	Inflammation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1324-1340.	2.8	273
138	Cardiac Troponin and the True-False-Positive. <i>JACC: Case Reports</i> , 2020, 2, 461-463.	0.6	4
139	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1243-1262.	4.4	13
140	The Need to Innovate and Accelerate Clinical Trial Performance. <i>Journal of the American College of Cardiology</i> , 2020, 76, 14-16.	2.8	2
141	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1244-1258.	2.8	322
142	Nepriylsin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 559-566.	3.1	15
143	Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1003-1013.	2.8	49
144	Soluble Urokinase Receptor and Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 382, 416-426.	27.0	149

#	ARTICLE	IF	CITATIONS
145	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>European Journal of Heart Failure</i> , 2020, 22, 1357-1365.	7.1	66
146	Omics phenotyping in heart failure: the next frontier. <i>European Heart Journal</i> , 2020, 41, 3477-3484.	2.2	48
147	Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6495-6499.	3.6	7
148	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
149	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1577-1581.	1.6	2
150	The Challenges of NT-proBNP Testing in $\text{AHFpEF}$ . <i>JACC: Heart Failure</i> , 2020, 8, 382-385.	4.1	12
151	Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2726-2737.	2.8	51
152	Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2804-2815.	2.8	30
153	Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea. <i>JACC: Heart Failure</i> , 2020, 8, 415-422.	4.1	13
154	An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7550-7550.	1.6	4
155	Developments in Heart Failure With Reduced Ejection Fraction—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2215.	7.4	0
156	Increasingly Sensitive Troponin Assays: Is Perfect the Enemy of Good?. <i>Journal of the American Heart Association</i> , 2020, 9, e019678.	3.7	2
157	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
158	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 261-266.	4.4	7
159	Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays. <i>JAMA Cardiology</i> , 2019, 4, 1034.	6.1	84
160	Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 782-794.	4.1	113
161	Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. <i>ESC Heart Failure</i> , 2019, 6, 784-792.	3.1	43
162	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. <i>ESC Heart Failure</i> , 2019, 6, 1085-1087.	3.1	2

#	ARTICLE	IF	CITATIONS
163	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Medicine, 2019, 132, S21-S29.	1.5	2
164	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. American Journal of Cardiology, 2019, 124, S20-S27.	1.6	26
165	<i>De novo</i> heart failure: where the journey begins. European Journal of Heart Failure, 2019, 21, 1245-1247.	7.1	2
166	Clinical and Prognostic Significance of sST2 in Heart Failure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
167	Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation. Journal of Clinical Oncology, 2019, 37, 2778-2785.	1.6	64
168	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085.	7.4	403
169	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	2.8	54
170	Are Some Patients With Acute Heart Failure ANP-Deficient?. JACC: Heart Failure, 2019, 7, 899-901.	4.1	2
171	Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. Journal of the American College of Cardiology, 2019, 73, 251-260.	2.8	36
172	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	7.1	446
173	Performance of a clinical/proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus. Open Heart, 2019, 6, e000955.	2.3	9
174	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	1.8	28
175	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	1.7	24
176	Reply. Journal of the American College of Cardiology, 2019, 73, 2121-2122.	2.8	0
177	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2439-2450.	2.8	69
178	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. Journal of the American College of Cardiology, 2019, 73, 2135-2145.	2.8	26
179	Association of the New Peer Group Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Network Open, 2019, 2, e192987.	5.9	42
180	Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. Journal of the American College of Cardiology, 2019, 73, 1273-1284.	2.8	98

#	ARTICLE	IF	CITATIONS
181	Race/ethnicity and plasma NT-proBNP in black and white individuals: How it matters. International Journal of Cardiology, 2019, 286, 164-165.	1.7	0
182	Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. American Journal of Cardiology, 2019, 123, 1906-1914.	1.6	43
183	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-T predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	7.1	36
184	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
185	Misclassification of Myocardial Injury as Myocardial Infarction. JAMA Cardiology, 2019, 4, 460.	6.1	80
186	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clinical Cardiology, 2019, 42, 592-604.	1.8	5
187	Requiem for a Heavyweight. JACC: Heart Failure, 2019, 7, 318-320.	4.1	0
188	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. Journal of the American College of Cardiology, 2019, 73, 1059-1077.	2.8	103
189	Exercise-induced Changes in Soluble ST2 Concentrations in Marathon Runners. Medicine and Science in Sports and Exercise, 2019, 51, 405-410.	0.4	11
190	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. Critical Pathways in Cardiology, 2019, 18, 1-4.	0.5	5
191	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 2019, 21, 386-388.	7.1	24
192	Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy. Journal of Thoracic Disease, 2019, 11, 5362-5371.	1.4	7
193	Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 2411.	7.4	232
194	Clinical Implications of the New York Heart Association Classification. Journal of the American Heart Association, 2019, 8, e014240.	3.7	133
195	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
196	A clinical, proteomics, and artificial intelligence-driven model to predict acute kidney injury in patients undergoing coronary angiography. Clinical Cardiology, 2019, 42, 292-298.	1.8	33
197	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC: Heart Failure, 2019, 7, 158-168.	4.1	65
198	Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study. Heart Rhythm, 2019, 16, 928-935.	0.7	9

#	ARTICLE	IF	CITATIONS
199	Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography—Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>American Heart Journal</i> , 2019, 209, 36-46.	2.7	9
200	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 78-86.	1.7	22
201	Trivializing an Elevated Troponin. <i>Journal of the American College of Cardiology</i> , 2019, 73, 10-12.	2.8	16
202	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	1.7	32
203	Medication dosing for heart failure with reduced ejection fraction—opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296.	7.1	57
204	High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1047-1055.	5.3	46
205	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 3-11.	3.0	20
206	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. <i>Global Heart</i> , 2019, 14, 215.	2.3	24
207	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. <i>Current Heart Failure Reports</i> , 2018, 15, 37-43.	3.3	29
208	Single-Molecule Counting of High-Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular) Study. <i>Circulation</i> , 2019, 140, 1017-1024.	3.7	10
209	Delirium in the Cardiac Intensive Care Unit. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	44
210	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). <i>American Heart Journal</i> , 2018, 199, 130-136.	2.7	71
211	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. <i>International Journal of Cardiology</i> , 2018, 254, 215-221.	1.7	19
212	Evaluating Chest Pain in the Emergency Department. <i>Journal of the American College of Cardiology</i> , 2018, 71, 617-619.	2.8	16
213	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12907.	3.4	13
214	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
215	MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression. <i>Circulation: Heart Failure</i> , 2018, 11, e004278.	3.9	32
216	Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>ESC Heart Failure</i> , 2018, 5, 240-248.	3.1	6

#	ARTICLE	IF	CITATIONS
217	Monitoring Biomarkers in Patients Receiving Neprilysin Inhibitors. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 8-16.	1.5	4
218	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 201-230.	2.8	235
219	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 215.	6.1	186
220	Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2540-2551.	2.8	118
221	Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?. <i>JACC: Heart Failure</i> , 2018, 6, 570-572.	4.1	9
222	Time Is Muscle in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 295-297.	4.1	5
223	N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1191-1200.	2.8	136
224	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	2.8	50
225	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	2.2	26
226	Biomarkers in stable coronary artery disease. <i>American Heart Journal</i> , 2018, 196, 82-96.	2.7	39
227	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity score matched study. <i>European Journal of Heart Failure</i> , 2018, 20, 345-354.	7.1	92
228	Soluble ST2 in Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 41-48.	2.1	80
229	Predictors and outcomes of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 651-659.	7.1	91
230	Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. <i>JACC: Heart Failure</i> , 2018, 6, 273-285.	4.1	152
231	Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y <sub>12</sub> Inhibitors in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 538-544.	0.6	4
232	Plasma Glycoproteomic Study of Therapeutic Hypothermia Reveals Novel Markers Predicting Neurologic Outcome Post-cardiac Arrest. <i>Translational Stroke Research</i> , 2018, 9, 64-73.	4.2	8
233	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2551-2562.	2.8	20
234	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3200-3223.	2.8	251

#	ARTICLE	IF	CITATIONS
235	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	2.8	126
236	Moving the Needle Toward a More Personalized Means of Patient Care. <i>JAMA Cardiology</i> , 2018, 3, 1146.	6.1	0
237	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3370-3372.	2.8	102
238	Pulmonary Production of Soluble ST2 in Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005488.	3.9	52
239	Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study. <i>Open Heart</i> , 2018, 5, e000916.	2.3	8
240	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nephilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	3.9	40
241	A Stitch in Time. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2182-2184.	2.9	4
242	A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. <i>Journal of Cardiac Failure</i> , 2018, 24, 773-782.	1.7	18
243	Endurance exercise training attenuates natriuretic peptide release during maximal effort exercise: biochemical correlates of the athlete's heart. <i>Journal of Applied Physiology</i> , 2018, 125, 1702-1709.	2.5	5
244	Clinical Profile of Acute Myocardial Infarction Patients Included in the Hospital Readmissions Reduction Program. <i>Journal of the American Heart Association</i> , 2018, 7, e009339.	3.7	13
245	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 271, 324-330.	1.7	27
246	Endothelin-1 Measurement in Patients Undergoing Diagnostic Coronary Angiography—Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. <i>Clinical Chemistry</i> , 2018, 64, 1617-1625.	3.2	8
247	Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study. <i>Circulation</i> , 2018, 137, 2101-2103.	1.6	12
248	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	4.1	103
249	The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, G11-G20.	0.1	10
250	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2018, 273, 136-140.	1.7	11
251	A Meta-Analysis of Genome-Wide Association Studies of Growth Differentiation Factor-15 Concentration in Blood. <i>Frontiers in Genetics</i> , 2018, 9, 97.	2.3	26
252	Left Ventricular Thrombus After Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 642.	6.1	171

#	ARTICLE	IF	CITATIONS
253	Established and Emerging Roles of Biomarkers in Heart Failure. <i>Circulation Research</i> , 2018, 123, 614-629.	4.5	200
254	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1166-1170.	2.8	16
255	A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. <i>Clinical Cardiology</i> , 2018, 41, 903-909.	1.8	13
256	Type 2 Myocardial Infarction—Diagnosis, Prognosis, and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 433.	7.4	51
257	Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. <i>Europace</i> , 2017, 19, 1848-1854.	1.7	10
258	Renin-Angiotensin System Blockade in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 820-822.	2.8	4
259	A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1147-1156.	2.8	55
260	Meta-Analysis of Soluble Suppression of Tumor Necrosis Factor-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	4.1	104
261	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 206-208.	2.4	47
262	The Evolving Medical Complexity of the Modern Cardiac Intensive Care Unit. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2008-2010.	2.8	23
263	Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in) <i>Tj ETQq1 1 0.7843d 4 rgBT 20</i> <i>Overlook</i>	4.1	104
264	Using Biomarkers to Guide Heart Failure Therapy. <i>Clinical Chemistry</i> , 2017, 63, 954-957.	3.2	6
265	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
266	Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 120, 803-808.	1.6	3
267	Door-to-Furosemide Therapy in the ED. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3052-3054.	2.8	5
268	Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2646-2656.	2.8	75
269	Breaking Bad. <i>JACC: Heart Failure</i> , 2017, 5, 446-448.	4.1	5
270	Manuscripts Based on Datasets Shared by Clinical Research Studies. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1983-1985.	2.8	4



#	ARTICLE	IF	CITATIONS
271	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 704-712.	2.8	142
272	Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. <i>Critical Care Medicine</i> , 2017, 45, e666-e673.	0.9	25
273	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 924-932.	0.6	12
274	Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients With Chronic Systolic Heart Failure. <i>American Journal of Clinical Pathology</i> , 2017, 147, 461-472.	0.7	19
275	Evaluation of the CRUSADE Risk Score for Predicting Major Bleeding in Patients with Concomitant Kidney Dysfunction and Acute Coronary Syndromes. <i>CardioRenal Medicine</i> , 2017, 7, 179-187.	1.9	1
276	Type 2 myocardial infarction due to supply-demand mismatch. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 408-417.	4.9	22
277	The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study. <i>Clinical Trials</i> , 2017, 14, 128-139.	1.6	30
278	Clinical implementation of an emergency department coronary computed tomographic angiography protocol for triage of patients with suspected acute coronary syndrome. <i>European Radiology</i> , 2017, 27, 2784-2793.	4.5	26
279	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. <i>Clinical Chemistry</i> , 2017, 63, 211-222.	3.2	41
280	Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. <i>Clinical Chemistry</i> , 2017, 63, 386-393.	3.2	34
281	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 735-742.	4.1	30
282	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 713.	7.4	386
283	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
284	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17058.	30.5	136
285	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	27.0	1,099
286	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	2.1	11
287	The Many Faces of Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1569-1572.	2.8	33
288	Mind the Gap: Current Challenges and Future State of Heart Failure Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1434-1449.	1.7	19

#	ARTICLE	IF	CITATIONS
289	High-Sensitivity Cardiac Troponin I as a Gatekeeper for Coronary Computed Tomography Angiography and Stress Testing in Patients with Acute Chest Pain. <i>Clinical Chemistry</i> , 2017, 63, 1724-1733.	3.2	19
290	Strain Echocardiography. <i>Journal of the American College of Cardiology</i> , 2017, 70, 955-957.	2.8	12
291	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 280-286.	4.1	127
292	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	1.7	35
293	Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 121-130.	1.7	10
294	Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. <i>Circulation</i> , 2017, 135, 116-127.	1.6	90
295	Advances in Heart Failure Management: Improving Outcomes With Innovation. <i>Reviews in Cardiovascular Medicine</i> , 2017, 18, S1-S16.	1.4	0
296	Comparison of Risk Prediction With the <sc>CKD&EPI</sc> and <sc>MDRD</sc> Equations in Non&ESt</sc> Segment Elevation Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2016, 39, 507-515.	1.8	17
297	Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome*. <i>Critical Care Medicine</i> , 2016, 44, 1735-1743.	0.9	27
298	Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study. <i>International Journal of Cardiology</i> , 2016, 205, 43-49.	1.7	9
299	The Importance of Worsening Heart Failure in Ambulatory Patients. <i>JACC: Heart Failure</i> , 2016, 4, 749-755.	4.1	19
300	B-Type Natriuretic Peptide Testing in the Era of Nephilysin Inhibition: Are the Winds of Change Blowing?. <i>Clinical Chemistry</i> , 2016, 62, 663-665.	3.2	7
301	Insulin-Like Growth Factor Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 860-869.	4.1	58
302	Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy The BIOCRT Study. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1478-1484.	1.7	13
303	Troponins in equipoise. <i>European Heart Journal</i> , 2016, 37, 3333-3334.	2.2	1
304	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	42
305	Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 429-431.	2.4	9
306	The effects of optimism and gratitude on adherence, functioning and mental health following an acute coronary syndrome. <i>General Hospital Psychiatry</i> , 2016, 43, 17-22.	2.4	50

#	ARTICLE	IF	CITATIONS
307	Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. <i>JACC: Heart Failure</i> , 2016, 4, 808-815.	4.1	72
308	Circulating Concentrations of Orexin A Predict Left Ventricular Myocardial Remodeling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2238-2240.	2.8	12
309	Biomarkers to Predict Risk in Apparently Well Populations. <i>JAMA Cardiology</i> , 2016, 1, 528.	6.1	2
310	Circulating Proneurotensin Concentrations and Cardiovascular Disease Events in the Community. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1692-1697.	2.4	50
311	A Positive Psychology Intervention for Patients with an Acute Coronary Syndrome: Treatment Development and Proof-of-Concept Trial. <i>Journal of Happiness Studies</i> , 2016, 17, 1985-2006.	3.2	84
312	Effects of Optimism and Gratitude on Physical Activity, Biomarkers, and Readmissions After an Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 55-63.	2.2	86
313	ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population. <i>American Journal of Clinical Pathology</i> , 2016, 145, 203-210.	0.7	8
314	Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department. <i>European Heart Journal</i> , 2016, 37, 2397-2405.	2.2	16
315	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 204, 242-247.	1.7	26
316	Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. <i>Atherosclerosis</i> , 2016, 248, 245-251.	0.8	53
317	Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. <i>Value in Health</i> , 2016, 19, 185-191.	0.3	26
318	Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. <i>American Journal of Medicine</i> , 2016, 129, 96-104.e7.	1.5	51
319	N-terminal pro-B-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 366-376.	1.8	16
320	Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. <i>European Journal of Heart Failure</i> , 2015, 17, 1252-1261.	7.1	95
321	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. <i>European Journal of Heart Failure</i> , 2015, 17, 1114-1123.	7.1	49
322	Can copeptin emerge from the growing shadow of the troponins?. <i>European Heart Journal</i> , 2015, 36, 333-336.	2.2	5
323	Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 613-21.	2.3	25
324	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. <i>International Journal of Cardiology</i> , 2015, 184, 337-343.	1.7	92

#	ARTICLE	IF	CITATIONS
325	Cystatin Câ€‘based <scp>CKDâ€‘EPI</scp> Equations and Nâ€™Terminal Proâ€™Bâ€™Type Natriuretic Peptide for Predicting Outcomes in Acutely Decompensated Heart Failure. <i>Clinical Cardiology</i> , 2015, 38, 106-113.	1.8	17
326	Validaci3n de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 80-81.	1.2	4
327	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 80-81.	0.6	3
328	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 355-361.	1.7	31
329	Outcomes of Patients With Acute Decompensated Heart Failure Managed by Cardiologists Versus Noncardiologists. <i>American Journal of Cardiology</i> , 2015, 115, 466-471.	1.6	40
330	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluidâ€™Homeostasis, Inflammation, and Renal Injury. <i>JACC: Heart Failure</i> , 2015, 3, 30-39.	4.1	70
331	The Biology of ST2: The International ST2 Consensus Panel. <i>American Journal of Cardiology</i> , 2015, 115, 3B-7B.	1.6	216
332	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibitâ€™Circulating Nephrylsin Activity inâ€™Heartâ€™Failure. <i>JACC: Heart Failure</i> , 2015, 3, 629-636.	4.1	72
333	Biomarkers in Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 514-525.	0.6	21
334	What to Expect When Measuring High-Sensitivity Troponin. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1665-1667.	2.8	13
335	The International ST2 Consensus Panel: Introduction. <i>American Journal of Cardiology</i> , 2015, 115, 1B-2B.	1.6	4
336	Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. <i>Clinica Chimica Acta</i> , 2015, 445, 73-78.	1.1	17
337	Use of the Patient Health Questionnaire-9 and a Detailed Suicide Evaluation in Determining Imminent Suicidality in Distressed Patients With Cardiac Disease. <i>Psychosomatics</i> , 2015, 56, 181-189.	2.5	20
338	Biomarcadores en la insuficiencia cardiaca aguda. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 514-525.	1.2	29
339	ST2 in Pulmonary Disease. <i>American Journal of Cardiology</i> , 2015, 115, 44B-47B.	1.6	22
340	ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. <i>American Journal of Cardiology</i> , 2015, 115, 70B-75B.	1.6	80
341	Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. <i>American Heart Journal</i> , 2015, 169, 572-578.e1.	2.7	23
342	Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2015, 169, 404-411.e3.	2.7	32

#	ARTICLE	IF	CITATIONS
343	The Potential Role of Natriuretic Peptideâ€“Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239.	1.7	16
344	ST2 in Heart Failure: Where Does This New Marker Fit in?. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 55-61.	1.5	0
345	Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2015, 104, 491-499.	3.3	54
346	Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 164-172.	2.4	30
347	ST2 and Prognosis in Acutely Decompensated Heart Failure: TheÂInternational ST2 Consensus Panel. <i>American Journal of Cardiology</i> , 2015, 115, 26B-31B.	1.6	75
348	State of the Art: Newer biomarkers in heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 559-569.	7.1	151
349	Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke. <i>Stroke</i> , 2015, 46, 2568-2575.	2.0	54
350	The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1017-1030.	1.5	37
351	Light Chains and the Failing Heart. <i>JACC: Heart Failure</i> , 2015, 3, 626-628.	4.1	3
352	Design and baseline data from the Gratitude Research in Acute Coronary Events (GRACE) study. <i>Contemporary Clinical Trials</i> , 2015, 44, 11-19.	1.8	13
353	hs-Troponin I Followed by CT Angiography Improves Acute Coronary Syndrome Risk Stratification Accuracy and Work-Up in Acute Chest Pain Patients. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1272-1281.	5.3	42
354	Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. <i>Biomarkers in Medicine</i> , 2015, 9, 433-441.	1.4	20
355	Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular SystolicÂDysfunction After AcuteÂMyocardial Infarction. <i>JACC: Heart Failure</i> , 2015, 3, 50-58.	4.1	77
356	Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 9-15.	1.7	14
357	Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. <i>Biomarkers in Disease</i> , 2015, , 731-756.	0.1	0
358	Abstract 17471: Cardiorenal Syndrome Patients With High NT-proBNP and Cystatin C Levels and Patients With Irreversible Cardiorenal Syndrome Identified by Persistently High Levels of Cystatin C Have Worse Outcomes in Cardiac Resynchronization Therapy: The BIOCRT Study. <i>Circulation</i> , 2015, 132, .	1.6	0
359	The Prognostic Value of Plasma Soluble ST2 in Hospitalized Chinese Patients with Heart Failure. <i>PLoS ONE</i> , 2014, 9, e110976.	2.5	10
360	Evidence of Uncoupling between Renal Dysfunction and Injury in Cardiorenal Syndrome: Insights from the BIONICS Study. <i>PLoS ONE</i> , 2014, 9, e112313.	2.5	32

#	ARTICLE	IF	CITATIONS
361	Biomarkers in ACS and Heart Failure: Should Men and Women Be Interpreted Differently?. <i>Clinical Chemistry</i> , 2014, 60, 35-43.	3.2	40
362	Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. <i>European Heart Journal</i> , 2014, 35, 1559-1567.	2.2	229
363	Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	19
364	Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>IJC Metabolic &amp; Endocrine</i> , 2014, 5, 11-18.	0.5	19
365	Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. <i>European Journal of Clinical Investigation</i> , 2014, 44, 643-651.	3.4	57
366	Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study. <i>Heart Rhythm</i> , 2014, 11, 2167-2175.	0.7	46
367	Correlation of concentrations of high-sensitivity troponin T and high-sensitivity C-reactive protein with plaque progression as measured by CT coronary angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2014, 8, 452-458.	1.3	17
368	Reversed Reverse Remodeling. <i>Circulation: Heart Failure</i> , 2014, 7, 388-390.	3.9	3
369	Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events. <i>JAMA Internal Medicine</i> , 2014, 174, 927.	5.1	161
370	When Cardiac Failure, Kidney Dysfunction, and Kidney Injury Intersect in Acute Conditions. <i>Critical Care Medicine</i> , 2014, 42, 2109-2117.	0.9	54
371	Red Cell Distribution Width and Additive Risk Prediction for Major Bleeding in Non-ST-segment Elevation Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 830-836.	0.6	5
372	Importance of Rigorous Evaluation in Comparative Biomarker Studies. <i>Journal of the American College of Cardiology</i> , 2014, 63, 167-169.	2.8	12
373	Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , 2014, 35, 16-24.	2.2	159
374	Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 250-261.	2.4	49
375	Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab. <i>Journal of the American College of Cardiology</i> , 2014, 63, 809-816.	2.8	438
376	Soluble ST2 and Galectin-3 in Heart Failure. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 87-97.	1.4	32
377	Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 65-72.	4.1	167
378	Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function?. <i>American Journal of Cardiology</i> , 2014, 114, 1543-1549.	1.6	60

#	ARTICLE	IF	CITATIONS
379	Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. <i>European Heart Journal</i> , 2014, 35, 3434-3441.	2.2	90
380	Natriuretic Peptides in Heart Failure. <i>Clinical Chemistry</i> , 2014, 60, 1040-1046.	3.2	21
381	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	4.1	106
382	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. <i>Journal of the American College of Cardiology</i> , 2014, 63, 778-785.	2.8	213
383	Reference Interval Evaluation of High-Sensitivity Troponin T and N-Terminal B-Type Natriuretic Peptide in Vietnam and the US: The North South East West Trial. <i>Clinical Chemistry</i> , 2014, 60, 758-764.	3.2	25
384	Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. <i>Clinical Chemistry</i> , 2014, 60, 1402-1408.	3.2	24
385	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. <i>American Heart Journal</i> , 2014, 167, 853-860.e4.	2.7	128
386	Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. <i>American Heart Journal</i> , 2014, 167, 109-115.e2.	2.7	85
387	Cardiac Markers Following Cardiac Surgery and Percutaneous Coronary Intervention. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 99-111.	1.4	3
388	Natriuretic Peptides in Heart Failure and Acute Coronary Syndrome. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 43-58.	1.4	36
389	Acute Coronary Syndrome Antiplatelet Alternatives in Clopidogrel Allergy. <i>Pharmacotherapy</i> , 2014, 34, e152-6.	2.6	8
390	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	4.1	81
391	Natriuretic Peptides in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 453-470.	2.1	27
392	Impact of Statin Use on Exercise-Induced Cardiac Troponin Elevations. <i>American Journal of Cardiology</i> , 2014, 114, 624-628.	1.6	28
393	Biomarkers and Optimal Management of Heart Failure in the Aging Population. , 2014, , 135-146.		0
394	Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. , 2014, , 1-21.		0
395	Critical research on biomarkers: what's new?. <i>Intensive Care Medicine</i> , 2013, 39, 1824-1828.	8.2	8
396	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	2.8	276

#	ARTICLE	IF	CITATIONS
397	The Role of B-Type Natriuretic Peptide Testing in Guiding Outpatient Heart Failure Treatment. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 397-409.	0.9	2
398	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
399	Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. <i>European Journal of Heart Failure</i> , 2013, 15, 1157-1163.	7.1	102
400	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	2.8	111
401	Natriuretic Peptides, Ejection Fraction, and Prognosis. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1507-1509.	2.8	16
402	Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2013, 1, 480-487.	4.1	103
403	Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 583-591.	1.7	41
404	Surfing the Biomarker Tsunami at JACC: Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 213-215.	4.1	31
405	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. <i>Revista Española De Cardiología</i> , 2013, 66, 132.e1-132.e15.	1.2	18
406	Biomarkers and diagnostics in heart failure. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2442-2450.	3.8	298
407	ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 493-500.	2.4	77
408	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	2.8	7,017
409	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. <i>International Journal of Cardiology</i> , 2013, 168, 2186-2194.	1.7	207
410	Depression and Cardiac Disease: Epidemiology, Mechanisms, and Diagnosis. <i>Cardiovascular Psychiatry and Neurology</i> , 2013, 2013, 1-14.	0.8	266
411	Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening. <i>Journal of the American Heart Association</i> , 2013, 2, e000399.	3.7	66
412	Using Biomarkers to Guide Heart Failure Management. <i>Cardiology in Review</i> , 2013, 21, 127-134.	1.4	9
413	Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome. <i>Critical Care Medicine</i> , 2013, 41, 2521-2531.	0.9	47
414	Are Serial BNP Measurements Useful in Heart Failure Management?. <i>Circulation</i> , 2013, 127, 500-508.	1.6	124



#	ARTICLE	IF	CITATIONS
415	Soluble Concentrations of the Interleukin Receptor Family Member ST2 and $\beta$ -Blocker Therapy in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1206-1213.	3.9	116
416	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807
417	Characterization and Prediction of Natriuretic Peptide "Nonresponse" During Heart Failure Management: Results From the ProBNP Outpatient Tailored Chronic Heart Failure (<sc>PROTECT</sc>) and the <sc>NT</sc>"Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (<sc>BATTLESCARRED</sc>) Study. <i>Congestive Heart Failure</i> , 2013, 19, 135-142.	2.0	39
418	Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. <i>European Journal of Heart Failure</i> , 2013, 15, 342-351.	7.1	70
419	Interleukin receptor family member ST2 concentrations in patients following heart transplantation. <i>Biomarkers</i> , 2013, 18, 250-256.	1.9	15
420	Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. <i>Clinical Chemistry</i> , 2013, 59, 1613-1620.	3.2	91
421	Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Circulation Journal</i> , 2013, 77, 2088-2096.	1.6	6
422	Natriuretic Peptides as Biomarkers in Heart Failure. <i>Journal of Investigative Medicine</i> , 2013, 61, 950-955.	1.6	32
423	Soluble ST2 predicts elevated SBP in the community. <i>Journal of Hypertension</i> , 2013, 31, 1431-1436.	0.5	42
424	Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. <i>Journal of Clinical Investigation</i> , 2013, 123, 4208-4218.	8.2	101
425	What Is the Role of Serial High-Sensitivity Troponin Measurements in Chronic Heart Failure?. <i>Clinical Chemistry</i> , 2012, 58, 1079-1081.	3.2	4
426	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
427	Pre-admission NT-proBNP improves diagnostic yield and risk stratification " the NT-proBNP for Evaluation of dyspnoeic patients in the Emergency Room and hospital (BNP4EVER) study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 99-108.	1.0	11
428	Use of biomarkers to guide outpatient therapy of heart failure. <i>Current Opinion in Cardiology</i> , 2012, 27, 661-668.	1.8	19
429	Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. <i>Clinical Chemistry</i> , 2012, 58, 1673-1681.	3.2	162
430	Interpreting Cardiac Troponin Results from High-Sensitivity Assays in Chronic Kidney Disease without Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2012, 58, 1342-1351.	3.2	125
431	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	2.2	2,447
432	Natriuretic Peptide Testing for Predicting Adverse Events Following Heart Failure Hospitalization. <i>Congestive Heart Failure</i> , 2012, 18, S9-S13.	2.0	30

#	ARTICLE	IF	CITATIONS
433	The Role of Natriuretic Peptides: From the Emergency Department Throughout Hospitalization. <i>Congestive Heart Failure</i> , 2012, 18, S5-8.	2.0	7
434	Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. <i>Critical Care</i> , 2012, 16, R135.	5.8	33
435	Red Cell Distribution Width Measurement: What Role Does It Have in Heart Failure?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 593-594.	0.6	1
436	Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 596-603.	2.6	653
437	Determinación del ancho de distribución eritrocitaria. Utilidad en la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 593-594.	1.2	5
438	Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. <i>Circulation</i> , 2012, 126, 1596-1604.	1.6	414
439	Emerging Biomarkers in Heart Failure. <i>Clinical Chemistry</i> , 2012, 58, 127-138.	3.2	227
440	Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. <i>European Heart Journal</i> , 2012, 33, 2265-2271.	2.2	256
441	Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: From the "Rule Out Myocardial Infarction Using Computer Assisted Tomography" (ROMICAT) trial. <i>American Heart Journal</i> , 2012, 163, 972-979.e1.	2.7	23
442	Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. <i>American Heart Journal</i> , 2012, 163, 1002-1010.	2.7	72
443	Red blood cell distribution width predicts new-onset anemia in heart failure patients. <i>International Journal of Cardiology</i> , 2012, 160, 196-200.	1.7	35
444	The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 40-50.	1.6	56
445	Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. <i>American Heart Journal</i> , 2012, 164, 793-799.e1.	2.7	54
446	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
447	Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in the Elderly: Results From the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>Journal of Cardiac Failure</i> , 2012, 18, 626-634.	1.7	70
448	Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. <i>European Heart Journal</i> , 2012, 33, 2197-2205.	2.2	130
449	Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 718-725.	7.1	228
450	Natriuretic Peptide Testing in Heart Failure. <i>Circulation</i> , 2011, 123, 2015-2019.	1.6	214

#	ARTICLE	IF	CITATIONS
451	Î2-Trace Protein and Cystatin C as Predictors of Long-Term Outcomes in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 57, 849-858.	2.8	66
452	Use of Amino-Terminal Pro-B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients With Chronic Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1881-1889.	2.8	323
453	Troponin I degradation in serum of patients with acute ischemic stroke. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 74-80.	1.2	4
454	A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. <i>American Heart Journal</i> , 2011, 162, 276-282.e1.	2.7	31
455	Use of Biomarkers to "Guide" Care in Chronic Heart Failure: What Have We Learned (So Far)?. <i>Journal of Cardiac Failure</i> , 2011, 17, 622-625.	1.7	15
456	Comparative Prognostic Value of Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Destabilized Heart Failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 365-372.	0.6	1
457	Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients. <i>American Journal of Cardiology</i> , 2011, 107, 1375-1380.	1.6	577
458	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. <i>Annals of Thoracic Surgery</i> , 2011, 92, 2118-2124.	1.3	41
459	Impact of a Depression Care Management Program for Hospitalized Cardiac Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 198-205.	2.2	83
460	Copeptin Does Not Add Diagnostic Information to High-Sensitivity Troponin T in Low- to Intermediate-Risk Patients with Acute Chest Pain: Results from the Rule Out Myocardial Infarction by Computed Tomography (ROMICAT) Study. <i>Clinical Chemistry</i> , 2011, 57, 1137-1145.	3.2	55
461	Biomarkers in the Management of Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 519-531.	0.9	22
462	ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure. <i>Current Heart Failure Reports</i> , 2010, 7, 9-14.	3.3	93
463	Importance of Biomarkers for Long-Term Mortality Prediction in Acutely Dyspneic Patients. <i>Clinical Chemistry</i> , 2010, 56, 1814-1821.	3.2	47
464	Hyponatremia, Natriuretic Peptides, and Outcomes in Acutely Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 354-361.	3.9	53
465	Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 826-832.	7.1	282
466	Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. <i>European Heart Journal</i> , 2010, 31, 1881-1889.	2.2	103
467	High-Sensitivity Troponin T Concentrations in Acute Chest Pain Patients Evaluated With Cardiac Computed Tomography. <i>Circulation</i> , 2010, 121, 1227-1234.	1.6	163
468	Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 129-136.	7.1	224

#	ARTICLE	IF	CITATIONS
469	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. <i>Biomarkers</i> , 2010, 15, 307-314.	1.9	16
470	Found in Translation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 251-253.	2.8	14
471	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2010, 63, 1171-1178.	0.6	31
472	Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects. <i>Biomarkers</i> , 2010, 15, 175-182.	1.9	8
473	Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>American Heart Journal</i> , 2010, 159, 532-538.e1.	2.7	58
474	Serum albumin and mortality in acutely decompensated heart failure. <i>American Heart Journal</i> , 2010, 160, 1149-1155.	2.7	148
475	ST2: a novel biomarker for heart failure. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 459-464.	3.1	60
476	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patientâ€”part 1. <i>Acute Cardiac Care</i> , 2009, 11, 3-42.	0.2	43
477	Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. <i>Circulation</i> , 2009, 119, 2545-2552.	1.6	747
478	Association between troponin T and impaired left ventricular relaxation in patients with acute decompensated heart failure with preserved systolic function. <i>European Journal of Echocardiography</i> , 2009, 10, 765-768.	2.3	24
479	Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea. <i>Circulation: Heart Failure</i> , 2009, 2, 311-319.	3.9	160
480	Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women. <i>Circulation</i> , 2009, 119, 2868-2876.	1.6	62
481	Usefulness of Natriuretic Peptide Testing for Long-Term Risk Assessment Following Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2009, 104, 287-291.	1.6	26
482	The evolution of the natriuretic peptides â€” Current applications in human and animal medicine. <i>Journal of Veterinary Cardiology</i> , 2009, 11, S9-S21.	0.9	36
483	Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma â€” The Presageâ„¢ ST2 assay. <i>Clinica Chimica Acta</i> , 2009, 409, 33-40.	1.1	214
484	Renal Clearance of B-Type Natriuretic Peptide and Amino Terminal Pro-B-Type Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2009, 53, 884-890.	2.8	142
485	Improving the Diagnosis of Acute Heart Failure Using a Validated Prediction Model. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1515-1521.	2.8	54
486	Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure. <i>Clinical Chemistry</i> , 2009, 55, 2098-2112.	3.2	187

#	ARTICLE	IF	CITATIONS
487	Natriuretic Peptides in the Diagnosis and Management of Acute Heart Failure. <i>Heart Failure Clinics</i> , 2009, 5, 489-500.	2.1	8
488	Natriuretic Peptide Testing for Heart Failure Therapy Guidance in the Inpatient and Outpatient Setting. <i>American Journal of Therapeutics</i> , 2009, 16, 171-177.	0.9	10
489	Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. <i>Critical Pathways in Cardiology</i> , 2009, 8, 146-150.	0.5	26
490	Plasma C-Reactive Protein Levels Are Associated With Improved Outcome in ARDS. <i>Chest</i> , 2009, 136, 471-480.	0.8	75
491	Natriuretic Peptide Guided Heart Failure Management. <i>Current Clinical Pharmacology</i> , 2009, 4, 87-94.	0.6	13
492	Evolution of amino-terminal Pro-B type natriuretic peptide testing in heart failure. <i>Drug News and Perspectives</i> , 2009, 22, 267.	1.5	9
493	Biology of the Natriuretic Peptides. <i>American Journal of Cardiology</i> , 2008, 101, S3-S8.	1.6	190
494	Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms. <i>American Journal of Cardiology</i> , 2008, 101, S29-S38.	1.6	85
495	Importance and Interpretation of Intermediate (Gray Zone) Amino-Terminal Pro-B-Type Natriuretic Peptide Concentrations. <i>American Journal of Cardiology</i> , 2008, 101, S39-S42.	1.6	36
496	The Differential Diagnosis of an Elevated Amino-Terminal Pro-B-Type Natriuretic Peptide Level. <i>American Journal of Cardiology</i> , 2008, 101, S43-S48.	1.6	65
497	Amino-Terminal Pro-B-Type Natriuretic Peptide Testing and Prognosis in Patients with Acute Dyspnea, Including Those with Acute Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, S49-S55.	1.6	38
498	Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for Inpatient Monitoring and Treatment Guidance of Acute Destabilized Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, S67-S71.	1.6	17
499	Understanding Amino-Terminal Pro-B-Type Natriuretic Peptide in Obesity. <i>American Journal of Cardiology</i> , 2008, 101, S89-S94.	1.6	50
500	The Editor's Roundtable: B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2008, 101, 1733-1740.	1.6	6
501	Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1458-1465.	2.8	335
502	Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 732-738.	1.7	179
503	Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROSÂ® amino-terminal pro-B type natriuretic peptide assay. <i>Clinica Chimica Acta</i> , 2008, 387, 48-54.	1.1	7
504	Independent and incremental prognostic value of multimarker testing in acute dyspnea: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. <i>Clinica Chimica Acta</i> , 2008, 392, 41-45.	1.1	52

#	ARTICLE	IF	CITATIONS
505	Response to Letter Regarding Article, "N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study". <i>Circulation</i> , 2008, 117, .	1.6	2
506	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. <i>European Heart Journal</i> , 2008, 29, 1011-1018.	2.2	71
507	Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea. <i>Archives of Internal Medicine</i> , 2008, 168, 741.	3.8	94
508	Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter. <i>Clinical Chemistry</i> , 2008, 54, 1107-1109.	3.2	3
509	Inflammatory Markers, Amino-Terminal Pro-Brain Natriuretic Peptide, and Mortality Risk in Dyspneic Patients. <i>American Journal of Clinical Pathology</i> , 2008, 130, 305-311.	0.7	8
510	Soluble ST2 Plasma Concentrations Predict 1-Year Mortality in Acutely Dyspneic Emergency Department Patients With Pulmonary Disease. <i>American Journal of Clinical Pathology</i> , 2008, 130, 578-584.	0.7	46
511	Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. <i>Critical Pathways in Cardiology</i> , 2008, 7, 83-121.	0.5	38
512	Erythropoietin in cardiovascular diseases: exploring new avenues. <i>Clinical Science</i> , 2008, 114, 289-291.	4.3	6
513	Sepsis and those who are "weak of heart". <i>Critical Care Medicine</i> , 2008, 36, 3108-3109.	0.9	3
514	Natriuretic Peptide Testing in Clinical Medicine. <i>Cardiology in Review</i> , 2008, 16, 240-249.	1.4	22
515	When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'? <i>European Heart Journal</i> , 2007, 28, 2960-2961.	2.2	12
516	N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. <i>Circulation</i> , 2007, 115, 3103-3110.	1.6	299
517	Amino-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 412-420.	3.2	38
518	Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome*. <i>Critical Care Medicine</i> , 2007, 35, 2484-2490.	0.9	51
519	Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. <i>American Heart Journal</i> , 2007, 153, 90-97.	2.7	71
520	Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure. <i>Clinica Chimica Acta</i> , 2007, 381, 145-150.	1.1	35
521	Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2007, 50, 607-613.	2.8	461
522	Case 28-2007. <i>New England Journal of Medicine</i> , 2007, 357, 1137-1145.	27.0	5

#	ARTICLE	IF	CITATIONS
523	Usefulness of Aminoterminal Pro-Brain Natriuretic Peptide Testing for the Diagnostic and Prognostic Evaluation of Dyspneic Patients With Diabetes Mellitus Seen in the Emergency Department (from the Tj ETQq1 1 0.784314 28BT /Over	3.8	125
524	Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea. Archives of Internal Medicine, 2007, 167, 400.	2.5	10
525	The Impact of Amino-Terminal Pro-Brain Natriuretic Peptide Testing on Hospital Length of Stay and Morbidity in Patients With Acute Decompensated Heart Failure. Archives of Pathology and Laboratory Medicine, 2007, 131, 473-476.	2.2	978
526	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. European Heart Journal, 2006, 27, 330-337.	2.8	356
527	Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Journal of the American College of Cardiology, 2006, 47, 91-97.	2.8	500
528	Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1217-1224.	2.8	136
529	Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1621-1627.	1.7	39
530	Neither Race nor Gender Influences the Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide Testing in Dyspneic Subjects: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Substudy. Journal of Cardiac Failure, 2006, 12, 452-457.	5.8	68
531	Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Critical Care, 2006, 10, R37.	2.7	63
532	A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. American Heart Journal, 2006, 151, 48-54.	2.7	17
533	Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: Clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. American Heart Journal, 2006, 151, 360-366.	0.6	34
534	Amino-Terminal Pro-Brain Natriuretic Peptide for the Diagnosis of Acute Heart Failure in Patients With Previous Obstructive Airway Disease. Annals of Emergency Medicine, 2006, 48, 66-74.	1.6	103
535	Usefulness of Intermediate Amino-Terminal Pro-Brain Natriuretic Peptide Concentrations for Diagnosis and Prognosis of Acute Heart Failure. American Journal of Cardiology, 2006, 98, 386-390.	1.6	88
536	Cost-Effectiveness of Using N-Terminal Pro-Brain Natriuretic Peptide to Guide the Diagnostic Assessment and Management of Dyspneic Patients in the Emergency Department. American Journal of Cardiology, 2006, 98, 800-805.	2.2	127
537	NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. European Heart Journal, 2006, 27, 839-845.	3.8	218
538	Utility of Amino-Terminal Pro-Brain Natriuretic Peptide Testing for Prediction of 1-Year Mortality in Patients With Dyspnea Treated in the Emergency Department. Archives of Internal Medicine, 2006, 166, 315.	3.1	4
539	Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. Expert Review of Molecular Diagnostics, 2006, 6, 649-662.	2.2	2
540	Is acute heart failure a highly prevalent orphan disease?. European Heart Journal, 2006, 27, 2619-2620.		

#	ARTICLE	IF	CITATIONS
541	Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure.. Cleveland Clinic Journal of Medicine, 2006, 73, 149-152.	1.3	26
542	Combination of D-Dimer and Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Evaluation of Dyspneic Patients With and Without Acute Pulmonary Embolism. Archives of Pathology and Laboratory Medicine, 2006, 130, 1326-1329.	2.5	14
543	Peripheral arterial disease, acute coronary syndromes, and early invasive management: The TACTICS TIMI 18 trial. Clinical Cardiology, 2005, 28, 238-242.	1.8	24
544	The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. American Journal of Cardiology, 2005, 95, 948-954.	1.6	1,046
545	Combined Use of Amino Terminal-Pro-Brain Natriuretic Peptide Levels and QRS Duration to Predict Left Ventricular Systolic Dysfunction in Patients With Dyspnea. American Journal of Cardiology, 2005, 96, 263-266.	1.6	12
546	Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. American Heart Journal, 2005, 149, 744-750.	2.7	239
547	The Effects of Ejection Fraction on N-Terminal ProBNP and BNP Levels in Patients With Acute CHF: Analysis From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Journal of Cardiac Failure, 2005, 11, S9-S14.	1.7	105
548	Acute Aortic Dissection Presenting With Congestive Heart Failure: Results From the International Registry of Acute Aortic Dissection. Journal of the American College of Cardiology, 2005, 46, 733-735.	2.8	46
549	Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. American Journal of Cardiology, 2004, 93, 843-847.	1.6	29
550	Comparison of aortic dissection in patients with and without Marfan's syndrome (results from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	72
551	Characterizing the young patient with aortic dissection: results from the international registry of aortic dissection (IRAD). Journal of the American College of Cardiology, 2004, 43, 665-669.	2.8	443
552	Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock*. Critical Care Medicine, 2004, 32, 1643-1647.	0.9	157
553	A Clinical and Biochemical Critical Pathway for the Evaluation of Patients With Suspected Acute Congestive Heart Failure. Critical Pathways in Cardiology, 2004, 3, 171-176.	0.5	19
554	Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. American Journal of Cardiology, 2003, 91, 457-461.	1.6	24
555	Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-STâ€“segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. American Heart Journal, 2003, 146, 764-774.	2.7	15
556	Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency. Circulation, 2002, 105, 2361-2366.	1.6	89
557	The brain and the cardiovascular system. , 2002, , 1952-1969.		0
558	A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. Journal of the American College of Cardiology, 2002, 39, 1518-1523.	2.8	145



#	ARTICLE	IF	CITATIONS
559	iatrogenic aortic dissection. American Journal of Cardiology, 2002, 89, 623-626.	1.6	177
560	Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). American Journal of Cardiology, 2002, 90, 1246-1249.	1.6	118
561	Elevation in serum troponin I predicts the benefit of tirofiban. Journal of Thrombosis and Thrombolysis, 2001, 11, 211-215.	2.1	27
562	Endothelial heparan sulfate is necessary but not sufficient for control of vascular smooth muscle cell growth. , 2000, 184, 93-100.		24
563	Effects of tirofiban plus heparin versus heparin alone on troponin i levels in patients with acute coronary syndromes. American Journal of Cardiology, 2000, 86, 713-717.	1.6	26
564	Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. , 1999, 7, 259-264.		20
565	Use of Natriuretic Peptides in the Diagnosis of Heart Failure. , 0, , 93-115.		0
566	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ, The, 0, , e068424.	6.0	18